DKSH Indonesia has entered into a strategic partnership with Genomize, a pioneering bioinformatics company, to bring cutting-edge genomic analysis technology to Indonesia. This collaboration will introduce Genomize’s SEQ Platform, a powerful next-generation sequencing (NGS) data analysis tool, to researchers and clinicians across the market, enhancing diagnostic precision.
Jakarta, Indonesia, October 27, 2025 – DKSH Indonesia has signed a strategic partnership agreement with Genomize, a leading provider of high-end digital solutions for bioinformatics analysis of NGS data. This collaboration marks a significant milestone in expanding access to advanced genomic technologies across Indonesia. The partnership leverages DKSH’s extensive network and deep expertise in the Life Sciences segment to provide a strong foundation for growth. Through this collaboration, Genomize can expand its reach and deliver precision genomic solutions via a single, coordinated channel.
Under the agreement, DKSH will provide sales and marketing services for Genomize’s SEQ Platform, a cloud-based, CE-IVD-certified variant annotation tool designed to deliver fast, reliable, and actionable insights for researchers and clinicians. The platform supports long-read, whole genome, and whole exome sequencing analyses for both germline and somatic variants and is compliant with Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR) standards.
With its proprietary Variant Prioritization algorithm, advance database functionalities, customizable multilingual reporting system, and intuitive user interface, the SEQ Platform empowers users to perform genomic analyses with up to 90% greater efficiency and 97% successful prioritization rate. Its exceptional Copy Number Variations (CNVs) analysis capabilities boast 96% sensitivity and 99% specificity, further enhancing diagnostic accuracy and speed.
“This strategic partnership with DKSH Indonesia marks a pivotal step in our mission to make advanced genomic insights more accessible across Indonesia,” said Dr. Ruçhan Karaman, Director of Strategy at Genomize. “DKSH Indonesia’s unparalleled expertise and their deep-rooted presence makes them the ideal partner for us to provide our cutting-edge solutions to the clinicians and researchers. Together, we are not just expanding our commercial reach; we are deepening our commitment to advancing precision medicine and improving patient outcomes throughout Indonesia.”
Fadjar Linawati, Managing Director, Singapore, Malaysia & Indonesia at DKSH, added: “We are proud to partner with Genomize to bring their innovative SEQ Platform to Indonesia. This collaboration underscores our commitment to advancing life sciences and delivering impactful solutions to healthcare professionals and researchers.”
About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Technology offers complete solutions for specialized scientific and industrial applications. With around 1,820 specialists, the Business Unit generated net sales of CHF 549 million in 2024. www.dksh.com/tec